AQST
NASDAQAquestive Therapeutics Inc.
Website
News25/Ratings5
Price$4.07+0.60 (+17.29%)
2026-01-202026-04-23
News · 26 weeks51-47%
2025-10-262026-04-19
Mix3490d
- Insider17(50%)
- SEC Filings7(21%)
- Other5(15%)
- Earnings3(9%)
- Leadership2(6%)
Latest news
25 items- INSIDERSEC Form 4 filed by Barber Daniel4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Boyd Peter E.4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Jung Cassie4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Toth A Ernest Jr4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Korczynski Sherry4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Braender Lori J4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zalewski Thomas A.3 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- SECAquestive Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- PRAquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual FilmReaffirms guidance to resubmit the Anaphylm NDA in Q3 2026Received clarifying feedback from the FDA on pharmacokinetic (PK) and human factor (HF) study designsFinal FDA meeting minutes expected by early May 2026 WARREN, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the receipt of preliminary comments and successful completion of an in-person Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the resubmission of the Company's New Drug
- SECAquestive Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- PRAquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance OfficerThomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly eight years as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective Apr
- INSIDERChief People Officer Boyd Peter E. was granted 80,000 shares and sold $124,414 worth of shares (29,814 units at $4.17), increasing direct ownership by 17% to 338,509 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERPresident and CEO Barber Daniel sold $753,965 worth of shares (180,677 units at $4.17) and was granted 262,000 shares, increasing direct ownership by 9% to 1,004,753 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief Legal Officer Braender Lori J was granted 80,000 shares and sold $167,346 worth of shares (40,102 units at $4.17), increasing direct ownership by 10% to 442,879 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSVP, Regulatory Affairs Cioffi Melina was granted 100,000 shares and sold $105,623 worth of shares (25,311 units at $4.17), increasing direct ownership by 37% to 274,867 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief Financial Officer Toth A Ernest Jr was granted 95,000 shares and sold $243,094 worth of shares (58,254 units at $4.17), increasing direct ownership by 11% to 376,112 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief Commercial Officer Korczynski Sherry was granted 75,000 shares and sold $65,687 worth of shares (15,741 units at $4.17), increasing direct ownership by 33% to 241,117 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief Operating Officer Jung Cassie was granted 80,000 shares and sold $191,086 worth of shares (45,791 units at $4.17), increasing direct ownership by 14% to 274,980 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief Development Officer Davis Matthew W. was granted 50,000 shares, increasing direct ownership by 100% to 100,000 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief Medical Officer Greenhawt Matthew J. was granted 75,000 shares (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERNew insider Greenhawt Matthew J. claimed ownership of 2,000 shares (SEC Form 3)3 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- PRAquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced an inducement grant for Matthew Greenhawt, MD, MBA, MSc, Chief Medical Officer of Aquestive Therapeutics (the "Company"), under the Company's 2022 Equity Inducement Plan. The inducement grant was approved by the Company's Compensation Committee. Under the Company's 2022 Equity Inducement Plan, Dr. Greenhawt will receive an equity award of 75,000 Restricted Stock Units (the "Inducement RSUs") and an equit
- SECSEC Form S-8 filed by Aquestive Therapeutics Inc.S-8 - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- SECSEC Form 10-K filed by Aquestive Therapeutics Inc.10-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- SECAquestive Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)